PluriSelect

Executive Summary

PluriSelect, a Boston-based biotechnology company founded in 2008, specializes in advanced cell separation and isolation technologies for research and clinical applications. The company's core focus is enabling precise selection of target cell populations, which is critical for cell therapy development and diagnostic assays. By providing high-purity, high-yield cell isolation tools, PluriSelect supports the growing demand for cell-based therapies, particularly in immunotherapy and regenerative medicine. The company's products are used by academic institutions, pharmaceutical companies, and clinical laboratories, positioning it as a key enabler in the cell therapy supply chain. Despite being privately held and having limited disclosed financials, PluriSelect's technologies address an essential step in cell manufacturing, a market projected to expand rapidly as cell therapies advance to earlier lines of treatment.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for a clinical-grade cell separation device60% success
• TBDStrategic partnership with a major cell therapy developer55% success
• Q3 2026Launch of a next-generation microfluidic cell sorting platform65% success